Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Company Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $70.80, for a total value of $35,400.00. Following the completion of the transaction, the vice president directly owned 72,924 shares of the company’s stock, valued at approximately $5,163,019.20. The trade was a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Tuesday, October 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $73.59, for a total value of $36,795.00.
• On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.79, for a total transaction of $35,395.00.

ANI Pharmaceuticals Trading Up 0.6%

Shares of NASDAQ:ANIP traded up $0.46 during mid-day trading on Friday, hitting $71.52. The company had a trading volume of 243,184 shares, compared to its average volume of 390,162. The company has a market capitalization of $1.64 billion, a PE ratio of 14.25, a price-to-earnings-growth ratio of 2.29 and a beta of 0.45. The firm has a fifty day moving average price of $72.33 and a 200 day moving average price of $77.05. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 2.33. ANI Pharmaceuticals, Inc. has a one year low of $67.14 and a one year high of $87.76.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.18 by $0.52. ANI Pharmaceuticals had a net margin of 11.22% and a return on equity of 28.34%. The firm had revenue of $290.78 million during the quarter, compared to analysts’ expectations of $280.59 million. During the same period last year, the company earned $2.04 earnings per share. The business’s revenue was up 27.6% on a year-over-year basis. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE purchased a new position in ANI Pharmaceuticals in the second quarter valued at about $15,154,000. NFJ Investment Group LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth approximately $2,766,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $1,449,000. Walleye Capital LLC acquired a new stake in ANI Pharmaceuticals during the second quarter valued at $8,784,000. Finally, Jupiter Topco LLC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth about $6,597,000. Institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ANIP. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 target price for the company. Canaccord Genuity Group lowered their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Oppenheimer began coverage on ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price objective on the stock. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Guggenheim increased their price objective on ANI Pharmaceuticals from $119.00 to $121.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $100.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.